---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Expected outcomes of therapy"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Expected outcomes of therapy. Topics: Sponsor-stated goal: one-time treatment of the genetic cause, Pivotal efficacy threshold: developmental milestone response rate, REVEAL Part A: functional gains over 12 or more months, Caregiver-defined meaningful outcomes of gene therapy, and 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Sponsor-stated goal: one-time treatment of the genetic cause

> “Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-2.2.2.7-2"></a>

### Pivotal efficacy threshold: developmental milestone response rate

> “A response rate of 33% (5 out of 15 patients) is the minimum threshold for success sufficient to reject the null hypothesis. Based on our natural history data analysis, the null hypothesis is that one out of 15 patients aged ≥ 6 years may gain/regain one of the 28 natural history defined developmental milestone without treatment, corresponding to a response rate of 6.7%.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.2.2.7-3"></a>

### REVEAL Part A: functional gains over 12 or more months

> “100% of patients (N=12, 6-21 years) in developmental plateau population of gained/regained ≥one DM”
> “At ≥12 months post-TSHA-102, a total of 310 functional gains and improvements were observed (~26 per patient), comprising 31 DMs and 279 additional skill gains/improvements”
> “Durable, multi-domain gains enable independent engagement in daily activities, reduce caregiver burden and enhance social engagement”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-2.2.2.7-4"></a>

### Caregiver-defined meaningful outcomes of gene therapy

> “According to caregivers, the gain or regain of a developmental milestone would be a meaningful functional improvement post-gene therapy, improving abilities to perform activities of daily living”
> “Incremental improvements were perceived as supporting child autonomy, safety, social interactions, pare burden of care and quality of life”

Source: [Keeley et al. (2025)](https://tayshagtx.com/wp-content/uploads/Every-Gain-Expanding-Possibilities-Caregiver-Insights-on-Meaningful-Improvement-in-Rett-Syndrome-Gene-Therapy-GT.pdf)

<a id="topic-2.2.2.7-5"></a>

### Payer expectations: durable functional gains

> “Payers emphasized the importance of demonstrating clinically meaningful, durable functional gains and improvements that translate into real-world benefits”

Source: [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm)

<a id="topic-2.2.2.7-6"></a>

### Uncertainty: durability, long-term safety, and clinically meaningful benefit

> “Determining what constitutes clinically meaningful benefit is equally difficult; families report that even modest gains in independence, communication, or daily living skills are profoundly valuable.”
> “Because gene therapy aims to deliver lifelong MeCP2 expression, long-term safety remains largely unknown. Open questions include durability of expression, feasibility of re-dosing in the context of anti-AAV immunity, potential for delayed toxicity from MeCP2 overexpression, risk of chronic CNS immune responses, and the theoretical possibility of insertional mutagenesis despite low AAV integration rates.”
> “Addressing these uncertainties will require decades-long surveillance; current protocols mandate 15-year follow-up for all treated individuals.”

Source: [Samanta (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12864443/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
